- Ongoing, recruitingTherapeutic exploratory (Phase II)
C0251013 - A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE CLINICAL EFFECT, PHARMACODYNAMIC, PHARMACOKINETIC AND SAFETY PROFILE OF PF-06823859 IN ADULT PARTICIPANTS WITH ACTIVE CLE OR SLE WITH CUTANEOUS MANIFESTATIONS
This study is testing a new medicine called PF-06823859 for adults with lupus that affects their skin. Researchers want to see if the medicine can reduce skin problems and if it's safe to use. Half the people will get the new medicine, and half will get a dummy medicine.
For: Active Cutaneous Lupus Erythematosus (CLE) or Systemic Lupus Erythematosus (SLE) With Cutaneous ManifestationsSpain · Greece - RecruitingPHASE3
A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
This study looks at a new medicine for muscle-weakening conditions called dermatomyositis (DM) and polymyositis (PM). It aims to see how well the medicine, called dazukibart, works to help people with these conditions and if it’s safe.
For: MyositisUnited States · Argentina · Bulgaria